- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
9,092 drug samples 'not of standard quality' in the last three years, JP Nadda
Different measures have been initiated to strengthen the coordination between Central and State government health agencies to improve the drug regulatory infrastructure The Union Health Minister, JP Nadda has updated that out of 2,05,448 drug samples tested from 36 states and union territories in the last three years, 9,092 samples were declared sub-standard, while 271 were found to be...
The Union Health Minister, JP Nadda has updated that out of 2,05,448 drug samples tested from 36 states and union territories in the last three years, 9,092 samples were declared sub-standard, while 271 were found to be spurious or adulterated.
As reported by PTI
In a written reply to Lok Sabha, Health and Family Welfare Minister JP Nadda said that 2,362 drug samples out of 58,537, 3,028 of 72,712 and 3,702 of 74,199 were found to be of substandard quality in 2012-13, 2013-14 and 2014-15 respectively.
Measures like increase in the number of sanctioned posts in Central Drug Standard Control Organisation (CDSCO), development of IT enabled system for online submission of clinical trial application, development of e-governance module for CDSCO and re-equipping the drug testing laboratories with state-of-art equipment, have been initiated, he added.
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country.She is a member of the Association of Healthcare Journalists. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751